Weakened surgical demand from price-conscious consumers and a rise in uninsured volumes stemming from health insurance exchange disenrollments proved an unexpectedly large drag on Community Health Systems' second quarter—and are now projected to continue through 2026.
The for-profit reported its miss Wednesday after market close, and in a Thursday morning earnings call affirmed the challenges and executives' thinking behind a revision to its 2026 guidance.
CHS is the first health system to officially release its Q2 numbers, though preliminary guidance released by HCA Healthcare last week gave investors and analysts an early warning that the estimated impacts of unextended Affordable Care Act enhanced premium subsidies are exceeding their models.
Some standout stats highlighted by CHS executives illustrating the challenge: Q2's same-store adjusted admissions increased 2.9% year over year, but half of that growth came from uninsured patients who bring little revenue to the company. Total uncompensated or self-pay patients comprised just under 5% of CHS' total visits during the same quarter a year ago (Q2 2025) but more than 6% during the most recent quarter, a jump executives said was more substantial than what it had seen when comparing Q1 year-ov
"In terms of collectability of self-pay, we only collect a few pennies on the dollar, ... we're effectively not recognizing any revenue on that self-pay business," Chief Financial Officer Jason Johnson said during the call.
Meanwhile, a Q1 trend of soft elective surgery demand among commercially insured patients has continued into the second period, for which executives highlighted a worsening consumer confidence index and the lower-than-average median household income of its markets.
"As gas prices go up, that has a pretty significant impact on disposable income for those households," CEO Kevin Hammons said during the call. "And healthcare seems to be one of the first things that people will delay, or at least attempt to delay if they can."
CHS did see some unexpected benefit this quarter due to Medicaid state-directed payment programs in Indiana and Florida. However, the payer and service mix headwinds were "more than enough to offset" those gains, and led to a net revenue per adjusted admission decline of 0.5% year over year.
CHS' shares were trading about 13% below the open as of early Thursday afternoon.
Of concern to analysts on the earnings call was just how much of the headwinds will continue through 2026. CHS, in issuing its new guidance, said it expects roughly the same level of earnings impact it saw during the first half to manifest in the second.
Net operating revenues for the year are now projected to land between $11.4 billion and $11.6 billion (previously $11.6 billion and $12 billion), adjusted EBITDA between $1.3 billion and $1.38 billion (previously $1.34 billion and $1.49 billion) and net loss per share between $1.25 and $1.10 (previously $0.60 to $0.00). Included in the guidance is between $50 million and $75 million of annual impact from the health insurance exchanges.
As for this past quarter, CHS reported net operating revenues of $2.83 billion. Net income attributable to stockholders was $70 million, or 50 cents per diluted share, but fell to a 19 cents per diluted share loss after excluding the facility sales and other adjusting items.
The reported net operating revenue came in $70 million below analysts' estimates, per Seeking Alpha, and adjusted earnings per share missed estimates by nine cents.
The latter also outpaced the five cents per share net loss the system had logged for the same period last year, despite a same-store net operating revenue increase of 2.4% and same-store admissions and adjusted admissions gains of 1.9% and 2.9%.
CHS also noted that it used $600 million from its hospital sales to repurchase some of its outstanding debt. Additionally, its cash flow has taken a hit as payers are increasingly triggering payment reviews early in the reimbursement process, executives noted during the call.
The results follow a red first quarter for CHS, on which it blamed a “temporary disruption in demand” across each of its markets related to consumers’ macroeconomic concerns. The company reported $12.5 billion total net operating revenues and a $509 million net gain ($3.77 per diluted share) across 2025 (or $1.19 per diluted share after adjustment).
The country’s largest for-profit health system, HCA Healthcare, already threw cold water on this quarter’s earnings season last week when it shared preliminary Q2 results suggesting a greater-than-expected payer mix decline tied to the Affordable Care Act exchanges. The system in April had predicted a $600 million to $900 million full-year unfavorable impact from disruptions stemming from the end of enhanced subsidies, but shifted its projections to a $1 billion to $1.2 billion drag.